Rediscovery of antimicrobial peptides as therapeutic agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryu, Minkyung | - |
dc.contributor.author | Park, Jaeyeong | - |
dc.contributor.author | Yeom, Ji-Hyun | - |
dc.contributor.author | Joo, Minju | - |
dc.contributor.author | Lee, Kangseok | - |
dc.date.accessioned | 2021-07-20T06:42:25Z | - |
dc.date.available | 2021-07-20T06:42:25Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1225-8873 | - |
dc.identifier.issn | 1976-3794 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/47694 | - |
dc.description.abstract | In recent years, the occurrence of antibiotic-resistant pathogens is increasing rapidly. There is growing concern as the development of antibiotics is slower than the increase in the resistance of pathogenic bacteria. Antimicrobial peptides (AMPs) are promising alternatives to antibiotics. Despite their name, which implies their antimicrobial activity, AMPs have recently been rediscovered as compounds having antifungal, antiviral, anticancer, antioxidant, and insecticidal effects. Moreover, many AMPs are relatively safe from toxic side effects and the generation of resistant microorganisms due to their target specificity and complexity of the mechanisms underlying their action. In this review, we summarize the history, classification, and mechanisms of action of AMPs, and provide descriptions of AMPs undergoing clinical trials. We also discuss the obstacles associated with the development of AMPs as therapeutic agents and recent strategies formulated to circumvent these obstacles. © 2021, The Microbiological Society of Korea. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | The Korean Society for Mocrobiology / The Korean Society of Virology | - |
dc.title | Rediscovery of antimicrobial peptides as therapeutic agents | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12275-021-0649-z | - |
dc.identifier.bibliographicCitation | Journal of Microbiology, v.59, no.2, pp 113 - 123 | - |
dc.identifier.kciid | ART002680505 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000613720400001 | - |
dc.identifier.scopusid | 2-s2.0-85100074878 | - |
dc.citation.endPage | 123 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 113 | - |
dc.citation.title | Journal of Microbiology | - |
dc.citation.volume | 59 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | antimicrobial peptide | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | drug candidate | - |
dc.subject.keywordAuthor | drug delivery system | - |
dc.subject.keywordAuthor | SLAY | - |
dc.subject.keywordPlus | HOST-DEFENSE PEPTIDES | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | HUMAN LACTOFERRIN | - |
dc.subject.keywordPlus | ANTIBACTERIAL ACTIVITY | - |
dc.subject.keywordPlus | METHICILLIN-RESISTANT | - |
dc.subject.keywordPlus | HUMAN CATHELICIDIN | - |
dc.subject.keywordPlus | DISULFIDE BONDS | - |
dc.subject.keywordPlus | LINEAR ANALOGS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.